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retracted, ischemic glomeruli, with capillary lumina narrowed
by a swollen endothelium or occluded by packed erythrocytes
and thrombi (Fig. 1). The capillary walls were markedly thick-
ened with many double contours. The tubular cells were dif-
fusely necrotic and detached from the basement membrane
with occasional vacuolar degeneration (Fig. 2). The interstitium
was mildly edematous and the arterioles were normal. A throm-
botic microangiography with glomerular involvement and an
acute tubular necrosis were diagnosed. Cyclosporine was with-
drawn and a course of daily exchanges with two liters of fresh
frozen plasma was started. Intravenous methylprednisolone
was rapidly tapered and withdrawn, azathioprine was replaced
by mycophenolate mofetil, and two 20 mg doses of Basiliximab
were injected four days apart. In the following days, several
transfusions of packed red blood cells were needed to treat
his symptomatic anemia. However, a diuresis promptly ensuedCASE PRESENTATIONS
and renal function progressively improved. Persistent (for two
A 26-year-old white man with IgA nephropathy and end- consecutive days) normalization in serum LDH and platelet
stage renal failure received a renal transplant from a cadaveric count was achieved after six plasma exchanges. Three weeks
donor 15 months ago. The surgery and the post-surgical course after admission, his hemoglobin concentration was 10.8 g/dL
were uneventful. He was immunosuppressed by steroids, cyclo- and serum creatinine 2.4 mg/dL, and he was discharged. He
sporine, and azathioprine. Four days later he was well. His blood was maintained on prednisone, 16 mg/day, and mycophenolate
pressure was 150/90 mm Hg; serum creatinine was 1.4 mg/dL, mofetil, 500 mg twice daily. His subsequent course was unevent-
and he was discharged. ful, the only exception being a cytomegalovirus reactivation
One week later, he experienced macrohematuria. The blood treated by intravenous ganciclovir. One year later he is well,
pressure was 125/85 mm Hg and his serum creatinine had and his serum creatinine is 1.2 mg/dL.
increased to 2.4 mg/dL. The hemoglobin concentration was
10.2 mg/dL; platelets, 120  103/L; and trough cyclosporine,
310 ng/mL. An ultrasound evaluation showed an enlarged, DISCUSSION
hyperechogenic graft with an increased resistive index (0.83)
Dr. Piero Ruggenenti (Assistant Professor, Negriand no evidence of hypoperfusion or urinary tract obstruction.
Bergamo Laboratories, Clincal Research Center for RareThree daily pulses of intravenous methylprednisolone (500 mg
Diseases, “Aldo e Cele Dacco´,” Villa Camozzi, Ranica;each) were planned. Two days later, however, the daily urinary
output had decreased to 500 mL; serum creatinine was 7.3 and Unit of Nephrology and Dialysis, Azienda Ospeda-
mg/dL; hemoglobin concentration, 9.1 g/dL; platelet count, liera Ospedali Riuniti, Bergamo, Italy): Hemolytic-ure-
88  103/l; and serum LDH, 985 IU/L (normal range, 230- mic syndrome (HUS) is a disease of microangiopathic
460 IU/L). He was admitted to the Nephrology Unit of the hemolytic anemia, thrombocytopenia, and renal failureBergamo Hospital, where two units of packed red cells were
that affects approximately 2 in 100,000 children world-transfused during a hemodialysis session and a percutaneous
wide every year. Peak incidence rates reach approxi-renal biopsy was performed. The tissue sample contained 10
mately 20 of 100,000 children in Argentina annually [1].
In western countries only 2% to 4% of affected childrenThe Nephrology Forum is funded in part by grants from Amgen,
progress to end-stage renal disease (ESRD). The out-Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; and Bristol-Myers Squibb Company. come is remarkably poorer in Latin America, where as
many as 20% of children require chronic renal replace-Key words: Shiga toxin, thrombocytopenia, cyclosporine, tacrolimus,
ment therapy. In adults, HUS is much less frequent,total-body irradiation, graft-versus-host disease, thrombotic microangi-
opathy. affecting no more than one in every 100,000 people per
year [2], but the disease is much more severe than in 2002 by the International Society of Nephrology
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Table 1. Forms of thrombotic microangiopathy Table 2. Post-transplant HUS
De novo HUSSTX-associated HUS
E. coli Drugs
CsA, tacrolimusS. dysenteriae
Non-STX associated HUS/TTP OKT3, ATG
Cyclophosphamide, methotrexateNeuraminidase-associated
Sporadic, idiopathic Viruses
Influenza AFamilial/relapsing
Genetically determined Parvovirus
CytomegalovirusSecondary
Pregnancy TBI
GVHDTTP
Severe pre-eclampsia/HELLP Syndrome Recurrent HUS
STX HUSPost partum HUS
HIV infection Non-STX
Genetically determinedSystemic disease
Antiphospholipid syndrome Non-genetically determined
Malignant hypertension
Systemic lupus erythematosus, Scleroderma
Cancer
Transplant
to be remarkably higher in transplant patients than inDrugs
the general population, most likely because of the clus-
tering of several risk factors in this particular group of
patients. In the setting of renal transplantation, HUS
children, leading to ESRD in approximately 50% of pa- can ensue for the first time (de novo post-transplant HUS)
tients [3]. This difference is largely because Shiga toxin or it can affect patients whose primary cause of ESRD
(STX)-associated HUS accounts for at least 80% of was HUS (recurrent post-transplant HUS; Table 2).
childhood, but no more than 5% of adult, cases. STX- De novo post-transplant HUS occurring in renal and
associated HUS is a relatively benign form of HUS pre- non-renal transplant recipients is usually triggered by
cipitated by infections with specific strains of E. coli or immunosuppressive drugs such as calcineurin inhibitors
S. dysenteriae [4]. The exotoxins (Shiga toxin or STX-1 [6] or, less frequently, by viral infections [7] and, specifi-
or -2) produced are toxic to the endothelial cell. On cally in renal transplant recipients, by acute vascular re-
the other hand, non-STX-associated forms, which are jection [8]. A peculiar form of de novo post-transplant
associated with a 50% to 100% progression rate to HUS affects recipients of bone marrow transplants
ESRD (Table 1), cluster in older subjects and account (BMT), usually in the setting of graft-versus-host disease
for the high morbidity and mortality rate frequently re- (GVHD) or of intensive GVHD prophylaxis, including
ported in adult series. Non-STX forms (Table 1) can be total-body irradiation (TBI; Table 2).
precipitated by certain drugs or can be associated with Recurrent post-transplant HUS is reported most fre-
concomitant diseases, but most often, as in familial or quently in patients who progressed to ESRD because of
recurrent forms, the non-STX forms lack a well-charac- non-STX HUS, in particular in those with recurrent/
terized inciting agent [1]. familial forms and with an underlying genetic abnormal-
Regardless of the underlying cause, activation of mi- ity predisposing to the disease. Whether the precipitating
crovascular endothelium plays a central role in the patho- factors associated with de novo HUS also contribute to
genesis of both STX- and non-STX–associated HUS [1]. disease recurrence in the renal graft is still a debated
This activation eventually leads to endothelium-blood question. In this Forum, I will discuss de novo HUS sep-
cell interaction and platelet thrombosis, with occlusion arately from recurrent post-transplant HUS, and I will
of small vessels and capillaries (thrombotic microangio- look at recurrences following STX-HUS separately from
pathy) of target organs and secondary organ failure [5]. those following non-STX forms.
Platelet consumption in the microvascular thrombi and
De novo post-transplant HUSred blood cell fragmentation in the damaged microvascu-
lature account for the thrombocytopenia and the mi- Multiple factors have been implicated in the develop-
croangiopathic hemolytic anemia that characterize the ment of post-transplant HUS. These factors include the
disease. use of calcineurin inhibitors, such as cyclosporine A (CsA)
or tacrolimus [6], or other immunosuppressive drugs such
Definitions and classification of post-transplant HUS as OKT3 [9], and systemic viral infections, particularly
Among secondary forms of HUS, post-transplant cytomegalovirus [7]. More recently, the association be-
HUS is being reported with increasing frequency and tween anticardiolipin antibody and post-transplant HUS
appears to affect a progressively increasing number of was described in a subset of hepatitis C virus–positive
renal allograft recipients [10].patients worldwide. The incidence of the disease appears
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The association between CsA and HUS was suggested The introduction of tacrolimus into clinical practice
in 1989 has been accompanied by reports of its successfulin 1981 by Shulman et al, who described three cases of
use in transplant recipients with CsA-associated HUSa rapidly fatal syndrome in BMT recipients receiving
[18]. As tacrolimus has become more widely used, how-CsA immunosuppression [11]. The patients developed
ever, cases of tacrolimus-induced HUS also have beenthrombocytopenia, hemolytic anemia, hypertension, and
recognized [19]. Since 1991, 24 patients have been identi-renal failure. Postmortem examination of the kidneys
fied, with a reported incidence of approximately 1% inshowed arteriolar and glomerular capillary thrombosis,
recipients of renal transplants, although the actual inci-mesangial sclerosis, and severe tubulointerstitial disease.
dence is probably higher [6].A similar syndrome was later recognized by Atkinson
Both CsA- and tacrolimus-associated HUS can pres-
et al in 1983, who described multiorgan failure with clini- ent with a spectrum of clinical signs ranging from variable
cal and histologic findings reminiscent of thrombotic degrees of hematologic or renal abnormalities to the full-
thrombocytopenic purpura (TTP) in two BMT recipients blown pentad of microangiopathic hemolytic anemia,
taking CsA [12]. Clinically, the patients presented with thrombocytopenia, neurologic signs, fever, and renal fail-
grand mal seizures, hemorrhagic pulmonary edema, and ure [6]. The hematologic changes can precede or follow
anuric renal failure. Plasma from one patient caused the signs of target organ dysfunction that occasionally
aggregation of normal platelets. At autopsy, the kidneys can be the only sign of the disease.
showed arteriolar and capillary thromboses, congested The disease affects about 6% of recipients of either
glomeruli, and tubular injury. With the more widespread allogenic or autologous BMT; more than 60% of these
are younger than 18 years. After an insidious onset, withuse of CsA, CsA-induced HUS also occurred in solid
only mild hemolysis and renal dysfunction, the diseaseorgan transplantation, first reported in liver allograft re-
usually progresses to oligoanuric renal failure and sec-cipients [13], then in renal [14] and cardiac transplant
ondary fluid retention with edema, pulmonary conges-recipients [15]. These findings suggested a causal rela-
tion, and severe hypertension, occasionally accompaniedtionship between this drug and the microangiopathic pro-
by hypertensive encephalopathy and generalized sei-cess, a hypothesis corroborated by evidence that HUS
zures. The most common glomerular abnormalities arealso occurs in patients receiving CsA for conditions not
ballooning of the glomerular lobules and disintegrationrelated to transplantation, such as uveitis, rheumatoid
of the mesangial matrix (mesangiolysis) combined with
arthritis, and psoriasis [16]. diffuse arteriolar necrosis and glomerular and arteriolar
After the first reports, Zarifian and coworkers in 1999 thrombosis [20].
carefully described the course of 26 CsA-associated cases In renal transplant recipients, the diagnosis occasion-
of HUS in 188 consecutive renal transplant patients over ally can be established on the basis of graft biopsies
a 3-year follow-up [17]. Only 2 of the 26 patients had performed to determine the cause of delayed graft func-
systemic evidence of microangiopathic hemolytic anemia tion or to rule out acute rejection, even in patients with
with increased lactate dehydrogenase (LDH), fragmented normal platelet count and no laboratory evidence of he-
erythrocytes in the peripheral smear, and decreased molysis. No organ system is spared by the vascular lesions
platelet count. The finding that the other 24 patients caused by CsA or tacrolimus. Pulmonary, dermatologic,
musculoskeletal, hepatic, and gastrointestinal involve-manifested no systemic clues to the diagnosis of HUS,
ment (presenting as hemorrhagic colitis) have been de-except for an acute rise of serum creatinine of 0.5 mg/dL
scribed in CsA-associated HUS [21].above baseline, underscored the importance both of con-
Although the pathogenesis of CsA-associated HUS issidering HUS in the differential diagnosis of patients
poorly understood, multiple CsA thrombotic effects havewith renal graft dysfunction, even in the absence of sys-
been implicated. These effects include a direct endothe-temic symptoms, and of performing a renal biopsy to
lial injury, demonstrated by increased LDH and 51chro-confirm the diagnosis. The heightened clinical suspicion
mium (51Cr) release from bovine aortic endothelial cellsand the liberal use of renal biopsy likely accounted for
exposed in vitro to CsA [22], and a reduction of both pros-
the relatively high frequency of the disease in this retro-
tacyclin synthesis and the prostacyclin-to-thromboxane
spective analysis (15%). Indeed, in less rigorously inves- A2 ratio; these changes lead to vasoconstriction, platelet
tigated series, the incidence of CsA-induced post-trans- aggregation, and thrombus formation [23]. Decreased
plant HUS ranged between 3% and 5% [6]. Of note, generation of activated protein C from endothelial cells,
disease frequency was even higher in patients treated and increased production of thromboplastin from mono-
with the microemulsion form of CsA, Neoral, which con- nuclear cells and of high-molecular-weight von Wille-
ceivably reflected the increased CsA bioavailability and brand factor (vWF) multimers from endothelial cells, can
serum peak levels achieved by Neoral as compared to further sustain the thrombotic process [23–25]. Although
less systemically studied, similar mechanisms have beenan older preparation (Sandimmune).
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involved in the pathogenesis of tacrolimus-induced HUS follow BMT and is sustained by excessive production of
[26]. Moreover, both CsA and tacrolimus have direct inflammatory cytokines and secondary widespread vas-
and indirect preglomerular constricting properties, the cular endothelial damage and organ dysfunction [33]. A
latter through a stimulatory effect on endothelin secre- suggested mechanism is that during GVHD, increased
tion [27], which in turn can result in increased vascular production of interferon gamma by activated lympho-
shear stress, abnormal vWF fragmentation, and platelet cytes stimulates monocytes to secrete interleukin-1 and
activation, with further amplification of the microangio- tissue necrosis factor alpha, which, in turn, can cause
pathic process [1]. endothelial damage and microangiopathy. This result is
Administration of OKT3 has been associated with de consistent with the finding that BMT-associated HUS is
novo post-transplant HUS but only rarely. Among the reported more frequently in patients with GVHD and
suggested mechanisms that might explain the thrombotic with evidence that the severity of the two syndromes is
properties of the drug are a four- to sixfold increased pro- very often correlated.
thombin activity, complement activation, and increased
TNF- release [9, 28]. Conditioning regimens including Recurrent post-transplant HUS
cyclophosphamide and methotrexate have been specifi-
The first reported case of recurrent HUS was a 51-
cally associated with post-BMT HUS. A direct endothe-
year-old man who received a living-related renal allo-lial toxic effect of these drugs has been claimed as the
graft from his son 5 months following the onset of post-inciting event of the disease [29].
HUS ESRD (abstract; Howard et al, Kidney Int 10:544,Several viruses, including influenza A virus [30], par-
1976). Primary allograft function was good until the thirdvoviruses [31], and cytomegalovirus [7, 32] have been
postoperative day, when the patient developed hemo-implicated in the pathogenesis of de novo HUS following
lytic anemia, thrombocytopenia, and oligoanuria. A re-bone marrow and solid organ transplantation. A parvovi-
nal transplant biopsy revealed extensive glomerular andrus B19 infection was recently reported as triggering four
arteriolar thrombus formation with no evidence of inter-cases of biopsy-proven HUS occurring 12 to 50 days after
stitial or perivascular cellular infiltrate. Following severalrenal transplantation [31]. Patients presented with fever,
isolated reports, in 1991 Hebert et al reviewed a seriesfatigue, arthralgias, aplastic anemia, and thrombocyto-
of 17 patients including 12 children younger than 9 yearspenia followed by deterioration of renal function that
old who had received a total of 27 renal transplants overrequired hemodialysis in three cases. Of note, the viral
a 20-year period [34]. Eleven grafts (9 from living relatedgenome was isolated in all the renal biopsy specimens.
Actually, parvoviruses can infect the endothelial cell donors) transplanted into 7 patients were lost because
through a specific binding to the P-antigen on the cell of biopsy-proven recurrences of HUS. In 3 additional
surface. The consequent endothelial injury can then sus- grafts, the disease remitted without sequelae. With the
tain the microangiopathic process. Similar mechanisms exception of 3 adult cases reported by Grino et al [35],
have been involved in the setting of infection with cyto- these poor outcomes were not confirmed in other series
megalovirus, which, in addition to directly damaging the (abstract; Pirson et al, Nephrol Dial Transplant 1:134,
endothelial cell, can sustain platelet adhesion to the mi- 1986; Repetto et al, Pediatr Nephrol 3:C185, 1989) [36].
crovascular wall by inducing the expression of adhesion In fact, an extremely variable rate of recurrence, ranging
molecules and the release of vWF [7, 32]. from 9% to 54%, has been reported in different series
Both TBI and GVHD play peculiar and independent [reviewed in 37]. Differentiating recurrent HUS from
roles in the pathogenesis of BMT-associated HUS. When other conditions (for example, renal vascular rejection,
the renal tolerance dose (2000 cGy) is exceeded or the acute CsA or tacrolimus nephrotoxicity, and malignant
endothelial sensitivity to radiation becomes more pro-
hypertension) largely accounted for these contrasting
nounced because of chemotherapy, the mitotic apparatus
findings. More reliable information on this controversialof the endothelial cell is damaged, and cellular mitosis
issue is derived by a recent meta-analysis of 10 selectedis invariably followed by cell death, with a consequent
studies in 159 grafts in 127 patients with a well-docu-disruption of the normal endothelial barrier and intra-
mented history of HUS in native kidneys and biopsy-vascular thrombosis [33]. When a critical number of cells
proven thrombotic microangiopathy in the transplantedis affected, usually 2 to 6 months after TBI, widespread
kidney; this analysis found an overall 27% recurrenceglomerular and arteriolar thrombosis and necrosis occur,
rate [37]. Older age at onset of HUS, shorter mean inter-with consequent acute and usually irreversible renal fail-
val between HUS and transplantation or ESRD, livingure (acute radiation nephritis).
related transplant, and treatment with calcineurin inhibi-Hemolytic-uremic syndrome also has been associated
tors were associated with an increased risk of recurrence.with GVHD. Actually, some clinicians consider GVHD
Conceivably, older age at onset and faster progression toand HUS two clinical manifestations of the same sys-
temic inflammatory response syndrome (SIRS) that can ESRD both reflected non-STX-associated HUS, whereas
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the increased risk associated with living related trans- HUS could not be ascertained. In all series, recurrences
plantation most likely disclosed a genetic (familial) pre- usually occurred within one or two months post trans-
disposition to the disease. plantation, with extremes of onset ranging from as short
In 1994, Miller et al pointed out that the risk of recur- as one day to as long as 13 years. Graft outcome is in-
rence is not simply a function of the patient’s age per variably poor, with graft loss reported in 80% to 90%
se, but rather is associated with the type of HUS that of cases, usually within two or three weeks after HUS
caused progression to ESRD [38]. In a series of 24 pa- recurrence [34, 38, 43].
tients who received 36 transplants, HUS recurred 16 Only a few studies, including individual case reports
times in 14 grafts in 11 patients. Of these 11 patients, without biopsy confirmation of disease recurrence, have
9 had non-diarrhea- (conceivably non-STX-) associated described the outcome of recurrent HUS in adults [42–44].
HUS and only one diarrhea- (conceivably STX-) associ- A recent retrospective study of the Ile-de-France Trans-
ated HUS. In one patient, the nature of the prodrome plantation Cooperative Group [43] contributed substan-
could not be determined. Combining their series with tially to clarifying this controversial issue. From 1975 to
previous reports, the authors found that in 25 of 26 pa- 1995, 16 patients with biopsy-proven HUS who received
tients with post-transplant recurrent HUS, a diarrheal a total of 25 allografts were identified. Of these, 9 patients
illness did not precede the original episode of HUS [38]. (56%) developed definite clinical and pathologic evi-
Thus, the high prevalence of STX-associated HUS in dence of recurrence in at least one graft, and 4 additional
children explains why recurrence is seldom or never re- patients showed clinical or pathologic evidence of recur-
ported in pediatric series. The opposite is true for adult rence that, however, could not be definitely distinguished
series, in which non-STX HUS accounts for at least 95% from acute vascular rejection. Of note, all the recur-
of HUS cases and is associated with a very high risk of rences were reported in patients with previous non-STX
post-transplant recurrence. HUS, whereas the only 3 disease-free patients had a
Retrospective analyses of European (abstract; Pirson) previous diagnosis of diarrhea- (conceivably STX-) asso-
[36], Argentinean (abstract; Repetto) [39], and North ciated HUS. As previously observed in children, recur-
American [40] series reported no recurrences in children rences were frequent and early, occurring within one
with post STX-HUS ESRD who received a renal trans- month after transplant in one-half the cases. An interest-
plant. This finding is probably because in this setting, re- ing finding, however, was that the risk of recurrence
exposure to the causative agent would be required to was remarkably lower in patients with pre-transplant
trigger disease recurrence. Evidence that anti-STX-neu- bilateral nephrectomy (50%) than in non-nephrecto-
tralizing antibodies persist over the long term in the mized patients (92%). These findings were confirmed
circulation of these patients renders this possibility ex-
and extended by an overview of 21 papers reporting an
tremely unlikely, even in areas where the disease is en-
overall 52% recurrence rate in 71 patients receiving ademic [41]. The few available reports suggest that even
total of 90 grafts [45]. Again, the recurrences primarilyadult patients with STX-HUS are virtually without risk
occurred in non-STX and familial forms, with an inci-of post-transplant recurrence. For instance, in our de-
dence that was 50% lower in pre-transplant nephrecto-partment, we have seen 3 adult patients with STX-HUS
mized (35%) than in non-nephrectomized (77%) pa-who received renal allografts, and all of them experi-
tients. Graft loss was a constant sequela and accountedenced prompt graft function without recurrence as long
for the poor overall one-year (43%) and 5-year (32%)as 5 years after follow-up.
kidney survival observed in the whole series of patients.Non-STX forms of HUS, in addition to having a poor
The outcome is even poorer in familial forms. Actually,outcome with a 50% to 100% incidence of ESRD, also
an overview [46] of three series [46–48], including 11 pa-retain a substantial risk of recurrence and graft loss after
tients with autosomal recessive inheritance of HUS re-renal transplant both in children and adults. Disease
ceiving 14 transplants, found 9 recurrences that, regard-recurrence and graft loss have been invariably observed
less of treatment, led to graft loss. Of note, the risk ofin the few patients who received one or more additional
recurrence was high regardless of treatment (with or with-transplants after the first one failed because of recurrent
out calcineurin inhibitors) or kidney source (cadaver orHUS [42]. A genetic predisposition has been advocated
living related donors). However, the finding that 5 of theto account for such a dramatic outcome.
recurrences occurred in living related transplants shouldOverall, children have a post-transplant recurrence
discourage the use of living related donors in this setting.rate ranging from 50% to 90% [34, 38, 43]. Of 61 children
A genetic background predisposing to microvascularreported to the North American Pediatric Renal Trans-
thrombosis has been demonstrated in rare forms of HUS.plant Registry, 5 developed recurrence of HUS within
Often occurring in families, these forms are character-the allograft [40]. Of these, 4 patients had progressed to
ized by frequent recurrences, both on native and trans-ESRD because of non-STX HUS. In the remaining one,
the differential diagnosis between STX and non-STX planted kidneys, and associated with a high risk of death
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or severe neurologic or renal sequelae [49–52]. Both auto- involvement both in adults [56] and children (Loirat C,
unpublished data) [1, 57]. Patients can transiently re-somal-recessive and autosomal-dominant modes of in-
heritance have been recognized, with precipitating events cover while the protease activity is restored by plasma
infusion or exchange, but generally they relapse after treat-such as pregnancy, virus-like disease, or sepsis being iden-
tified in some, but not all series [49–52]. Evidence that ment withdrawal. When affecting the kidney, repeated
relapses lead to progressive and irreversible renal dys-some of these patients recovered, at least transiently,
with plasma infusion or exchange, suggested that the one function (Loirat C, unpublished data). Disease recur-
rence has been reported even in a kidney graft and hasor more underlying genetic defects were the cause of one
or more abnormalities in plasma components essential to been associated with premature graft loss (Loirat C, un-
published data).the integrity of the microvascular circulation and/or to
the defense mechanism of the host endothelium against The clinical features of post-transplant HUS are few.
Anemia is usually mild, and thrombocytopenia is re-injurious agents. Finding reduced serum levels of the
third component of complement (C3) in a number of HUS ported in no more than 50% of patients. Renal dysfunc-
tion can be the only non-specific sign of a post-transplantcases and in some family members, but not in healthy con-
trols and their relatives, led Noris et al to suggest that disease recurrence. However, since concomitant diseases
such as acute rejection, CsA or tacrolimus nephrotoxic-the disease could be sustained by overactivity of the al-
ternative complement pathway that resulted in increased ity, or cytomegalovirus infection can confound the clini-
cal picture, the definite diagnosis almost invariably restsC3 consumption in the microcirculation [49]. Since low
C3 and decreased factor H bioavailability or activity are on the biopsy findings [58]. Typical changes include glo-
merular and arteriolar thrombosis, endothelial cell swell-almost invariably associated with recurrent/familial HUS,
increased C3 consumption might be the result of impaired ing and detachment from the basement membrane, glo-
merular ischemia and, in the healing phase, onion-skinfunction of factor H [49, 53]. Indeed, interaction of factor
H with sialic acid and other polyanions on human cells hypertrophy of the arteriolar walls. These changes, how-
ever, also can reflect an acute vascular rejection thatand tissues increases the affinity of factor H for C3b and
increases its inhibitory effect on the alternative pathway should always be considered in the differential diagnosis
with recurrent HUS, in particular when tubulitis andof complement activation. This control step protects host
cells from autolytic attack of the alternative complement interstitial infiltration are accompanied by severe endo-
vasculitic lesions affecting the entire vascular tree of thepathway, because complement activation induces the de-
position of C3b indiscriminately onto host and foreign graft (Fig. 3).
particles. This phenomenon applies particularly to endo-
Treatmentthelial cells, with their high surface density of heparan-
like glycosaminoglycans [54]. Thus, when an environmen- Treatment of post-transplant HUS rests on removal
of the inciting factor(s), relief of symptoms, and plasmatal trigger activates the alternative complement pathway,
modification of the heparan-binding capacity of mutated infusion or exchange. No other approach has proven
effective. Drug withdrawal or dose reduction is first-factor H might facilitate the occurrence of microvascular
thrombosis. More specifically, when the bioavailability line therapy for de novo CsA- or tacrolimus-associated
forms, but it is effective in fewer than 50% of patients. Aor the activity of factor H is congenitally defective, in-
tercurrent exposure to agents that damage the vascular remarkably higher success rate (84%) has been reported
with adjunctive plasma infusion or exchange [6, 17]. Aendothelium, such as certain viruses, bacteria, toxins, im-
munocomplexes, and drugs, results in uncontrolled C3bBb similar response rate, but in a much smaller series, was
reported with intravenous IgG infusion, which was givenconvertase formation and complement activation [55],
which causes microangiopathic damage and disease man- with the rationale of neutralizing hypothetical circulating
cytotoxic or platelet-agglutinating factors [59]. After re-ifestation. Immunologic and toxic endothelial injury as-
sociated with vascular rejection or treatment with cal- mission is achieved, patients who are rechallenged with
decreased doses of CsA or tacrolimus [60, 61], switchedcineurin inhibitors might explain why all renal transplant
patients with factor H abnormalities so far reported ex- from one drug to the other [62], or, finally, treated with
mycophenolate mofetil [63] have been sporadically re-perienced an early disease recurrence invariably fol-
lowed by graft failure [49–53]. ported to maintain adequate immunosuppression with-
out inducing disease recurrence. Recently, “compassion-A similar outcome was reported by Loirat and cowork-
ers in children with non-STX HUS and decreased vWF ate treatment” with rapamicin was associated with a
remarkably good outcome in 15 patients with CsA- orcleaving protease activity (Loirat et al, data presented
at the 12th Cong Int Pediatr Nephrol Assoc, Seattle, WA, tacrolimus-associated post-transplant HUS, with no pa-
tient requiring rapamicin withdrawal because of disease2001). When genetically determined, this abnormality
predisposes to repeated microangiopathic episodes that recurrence [abstract; Leichtman et al, Am J Transplant
1(Suppl 1):141, 2001]. Monoclonal anti-IL-2 receptorare usually associated with severe renal and neurologic
Fig. 3. Autopsy kidney section from a patient with recurrent post-Fig. 1. Glomerulus from a patient with de novo, CsA-associated, post-
transplant HUS or vascular rejection. The arterioles and all the glomeru-transplant HUS. Some glomerular capillaries are occluded by thrombi
lar capillaries are occluded by thrombi and erythrocytes. The intersti-containing packed erythrocytes. Other capillaries are surrounded by
tium is diffusely infiltrated by erythrocytes. A diagnosis of vasculardouble contours.
rejection rather than of recurrent HUS is suggested by the severe and
diffuse vascular involvement.
antagonists also can be a valid option for maintaining ade-
quate immunosuppression and avoiding the toxic effects
of calcineurin inhibitors. The outcome of de novo forms
occurring in the setting of viral infection parallels the
response to treatment of the underlying disease [30–32].
Despite intensive plasma therapy or rescue treatment
with plasma cryosupernatant or protein A immunoad-
sorption exchanges [64], the outcome of de novo forms
complicating BMT is still dramatically poor, with a mor-
tality rate close to 90%. In addition to the severity of
the microangiopathic process—quantified on the basis
of serum LDH levels and percentage of circulating frag-
mented erythrocytes—infection, progressive GVHD, or
relapse of the underlying disease might account for these
discouraging figures [19].
Equally poor is the outcome of recurrent forms of
post-transplant HUS that usually do not respond to any
Fig. 2. Glomerulus from a patient with de novo, CsA-associated, post-
transplant HUS. The vascular pole and a capillary of the tuft are oc-
cluded by thrombi containing packed erythrocytes. The tubular cells
are diffusely necrotic and detached from the basement membrane with
occasional vacuolar degeneration. The interstitium is mildly edematous.
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type of therapy and are associated with graft loss close Dr. Adalberto Sessa (Head, Division of Nephrology,
Ospedale Vimercate, Vimercate, Italy): How frequent isto 100%.
On the basis of these data, renal transplantation should neurologic involvement in post-transplant HUS, either
in de novo or recurrent forms?be considered an effective and safe treatment of ESRD
for patients with STX-associated HUS, but considered Dr. Ruggenenti: Neurologic and other extrarenal
manifestations of the disease are relatively uncommon inwith extreme caution in patients with non-STX-forms.
In particular, until new strategies that can effectively post-transplant HUS. However, central nervous system
involvement has been described in adults and children andlimit or prevent the risk of recurrence in the graft become
available, renal transplantation is contraindicated in fa- has presented with spontaneous cerebral hemorrhage (ab-
stract; Mochon et al, J Am Soc Nephrol 1:765, 1990) [66].milial/relapsing forms and in all cases with a well-charac-
terized genetic abnormality predisposing to the disease. Dr. Arrigo Schieppati (Unit of Nephrology and Dial-
ysis, Ospedali Riuniti di Bergamo and Clinical Research
Center for Rare Diseases “Aldo e Cele Dacco´,” Ranica,
QUESTIONS AND ANSWERS
Italy): In the case you presented, I believe that with-
Dr. Marina Noris (Negri Bergamo Laboratories, Ber- drawal of cyclosporine was likely the major step in achiev-
gamo, Italy): Piero, you have shown that patients with ing disease remission. Whether plasma exchange had a
factor H mutations have a 100% post-transplant recur- specific, additional role seems questionable. Do we have
rence rate. However, other cases of familial HUS that any evidence that plasma infusion or exchange is useful
are genetically determined do not recur [46]. How do in post-transplant HUS, and is there any other poten-
you explain such a different outcome? tially effective therapy?
Dr. Ruggenenti: The different post-transplant recur- Dr. Ruggenenti: You are right. As the first treatment
rence rates depend on the different biochemical changes step, one does have to eliminate any precipitating factor.
sustained by the genetic mutation. When these changes We have no definite evidence that plasma exchange was
affect a circulating factor (such as factor H) that inter- effective in our patient or that it improves the outcome
feres with the thromboresistance of normal endothelium, of post-transplant HUS. Plasma infusion or exchange is
the same conditions that promoted the disease in native used in this setting because of the results achieved in
kidneys also might affect the transplanted kidney. The the treatment of forms affecting native kidneys. Adding
converse might be true when the biochemical change plasma infusion/exchange might limit the microangio-
affects fixed molecules within the endothelium itself. In pathic process in cases sustained by plasma abnormalities
this case, since the transplanted kidney does not have (such as defective factor H activity) that can be corrected
the abnormality, the disease might not recur. However, by normal plasma infusion. Whether this approach is
a more precise answer will be possible only when the effective in other familial/recurrent forms is a reasonable
mutations involved in familial forms that do not recur hypothesis, but not a proven one. Other treatments, such
are identified. as immunoperfusion—perfusion of autologous plasma
Dr. Jordan J. Cohen (President, Association of Amer- over filters containing staphylococcal protein A [64]—
ican Medical Colleges, Washington, DC): We know that have been attempted. There is no reason, however, to
only a small proportion of patients exposed to Shiga believe that this procedure offers any advantage as com-
toxin develop HUS. This might suggest a genetic pre- pared to plasma exchange. Finally, as I mentioned, high-
disposition in these patients. Might this genetic trait pre- dose intravenous immunoglobulin infusion has been re-
dispose to disease recurrence even after renal trans- ported effective in some cases associated with CMV in-
plantation? fection [32].
Dr. Ruggenenti: Several factors affect the risk of de- Dr. Cohen: You showed us quite convincingly that
veloping HUS after exposure to STX. Some of these patients with HUS associated with factor H abnormali-
might be environmental factors such as the amount of the ties should not receive renal transplants because HUS is
toxin or treatments with antimotility agents or antibiotics highly likely to recur. However, you also suggested that
that, when used to treat STX-induced hemorrhagic coli- patients with other non-STX-associated forms should not
tis, might subsequently favor the onset of full-blown receive transplants either. Do you mean that in these cases
HUS [65]. Other factors, however, are likely genetically there also is a strong genetic predisposition to recurrence?
determined and might predispose to the disease even Dr. Ruggenenti: I am convinced that most non-STX-
when exposure to STX occurs after the transplant. Since associated forms have a strong genetic predisposition
patients who received a renal transplant because of even if the genetic abnormalities predisposing to the
ESRD secondary to STX-associated HUS are few, the disease have not yet been recognized. I believe that a
data in available series are too small to definitely estab- transplant in these patients is unsafe and should not be
lish the role of genetic predisposition in post-transplant performed. An exception to this rule might be secondary
forms of HUS precipitated by some drugs, which can berecurrence.
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avoided after transplantation. For sure, a renal trans- that in non STX-cases persisted even after remission of
the acute episode. They were children with recurrentplant is contraindicated in familial and recurrent forms.
Dr. Giuseppe Remuzzi (Director, Negri Bergamo Lab- HUS who had their first episode at birth and who had
exactly the same genetic abnormality described by Fur-oratories and Unit of Nephrology and Dialysis, Ospedali
Riuniti di Bergamo): Piero, I’d like to offer another argu- lan et al in adult TTP [72]. These findings lead me to
believe that I should maintain the stance I took at thement in support of your concept of avoiding living-re-
lated donor transplants. Living-related donors might Forum I delivered in 1987: that HUS and TTP are, in
fact, a single entity [68].have the same genetic abnormality that contributes to
local complement activation. Locally formed comple- That HUS and TTP are just two different expressions
of the same disease is consistent with the reports ofment can be important in determining acute rejection,
glomerulonephritis, and progression of renal disease familial cases that, despite the same genetic abnormality,
were classified as HUS or TTP in different members of[67]. The possibility that the donor might have a factor
H abnormality predisposing to such local complement the same family [73]. Even more convincing are the re-
ports of different episodes of recurrent disease in theactivation thus is an additional reason to avoid living-
related transplantation. same patient that were on some occasions defined as
HUS and in others as TTP, even if they were obviouslyDr. Cohen: Piero, you discussed the difficulty in differ-
entiating post-transplant HUS from acute vascular rejec- associated with the same genetic defect [74]. In all re-
ported cases, the term HUS tended to be preferred intion. How is differentiation possible, and what are the
clinical issues you can rely on? children with renal insufficiency and the term TTP in
adults with predominantly neurologic involvement. Thus,Dr. Ruggenenti: Distinguishing between HUS and
vascular rejection is important because treatment is dif- with the only exception being STX-associated HUS, all
the other forms cannot be classified as HUS or TTP justferent and an incorrect diagnosis might result in loss of
the graft. Unfortunately, differential diagnosis is ex- on the basis of a specific genetic abnormality.
Dr. Norberto Perico (Clinical Research Center fortremely hard on clinical grounds, as both cases can be
associated with acute renal failure, microangiopathic he- Rare Diseases “Aldo e Cele Dacco´”): Piero, you have
shown that cyclosporine might have a direct toxic effectmolytic anemia, and thrombocytopenia. Fever and graft
tenderness are more frequent with vascular rejection but on the endothelial cell and that, by up-regulating the
expression of adhesion molecules, CsA might favor leu-are not specific. In addition, even the histologic diagnosis
is problematic because in both cases typical signs of kocyte adhesion to the endothelial surface and cause
consequent vascular damage and thrombosis. The inthrombotic microangiopathy can be observed. Vascular
changes might be more prominent with vascular rejec- vitro effect, however, is observed at concentrations that
largely exceed those usually found in the circulation oftion, but this is not a definite criterion for vascular rejec-
tion. Cellular infiltration and tubulitis might suggest a transplant patients. Thus, in this clinical setting, a direct
toxic effect should seldom play a major role unless it isdiagnosis of vascular rejection, but these changes, albeit
less prominent, also can be observed in HUS. accompanied by concomitant ischemic or immune dam-
age. However, at pharmacologic doses, cyclosporine hasDr. Cohen: Beppe, putting aside the difficulty in dif-
ferentiating these conditions, in your Nephrology Forum a potent vasoconstrictive effect that can result in renal
hypoperfusion and ischemia [75]. Increased release ofof 15 years ago, you discussed the relationship between
HUS and TTP [68]. What is your opinion now? Are endothelin and other mediators might then amplify en-
dothelial damage and sustain the microangiopathic pro-these two diseases related or not?
Dr. Remuzzi: Two papers published in the New En- cess.
Dr. Ruggenenti: This is an important point. As yougland Journal of Medicine showed that patients with
TTP have a decreased vWF-cleaving protease activity pointed out, at usual blood levels, cyclosporine induces
a potent pre-glomerular vasoconstriction. Extreme vas-associated with abnormally large vWF multimers that
predispose to intravascular thrombosis [69, 70]. In con- cular lumina narrowing results in accelerated blood flow
and increased shear stress. Shear stress might favor plate-trast, vWF-cleaving protease activity was reported to be
normal in patients with HUS. Thus, it has been claimed let activation and vWF proteolysis to fragments that
more effectively bind activated platelets [76]. This se-that a decreased vWF-cleaving protease activity differen-
tiates patients with TTP from those with HUS [71]. How- quence of events favors the microangiopathic process,
especially when the physiologic thromboresistance ofever, I believe that this is an oversimplification. Miriam
Galbusera from our group studied several cases (ab- vascular endothelium is decreased by concomitant isch-
emic, immune, or toxic damage.stract; Mannucci et al, J Am Soc Nephrol 12:115A, 2001)
and Dr. Loirat (unpublished data) six cases (one STX- Dr. Carla Zoja (Negri Bergamo Laboratories): Some
years ago we found in our laboratories that cyclosporineassociated and five non-STX-associated) of HUS associ-
ated with undetectable vWF-cleaving protease activity increases the adhesion of leukocytes to endothelial cells
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in culture under physiologic flow conditions, up-regulat- these patients transplants. However, I have to say that,
unlike the several HUS cases with factor H mutationsing the endothelial expression of adhesion molecules
[77]. Do you think that this sequence of events might reported to recur, to the best of my knowledge, only one
child with recurrent HUS associated with defective vWF-have a role in the pathogenesis of cyclosporine-associ-
ated post-transplant HUS? cleaving protease activity has received a renal transplant
(Loirat C, unpublished data). This child lost the kidneyDr. Ruggenenti: Yes, I think that up-regulation of
adhesion molecule expression on endothelial cell surface because of a post-transplant recurrence of HUS. This is
only one case, but this is enough in my opinion to prohibitand secondary leukocyte adhesion to endothelial surface
might play a major role in the sequence of events leading transplantation in this setting as well.
Dr. Miriam Galbusera (Negri Bergamo Labora-to microangiopathic thrombosis. These changes have
been clearly demonstrated in STX-associated HUS. Neu- tories): In regard to the issue of decreased vWF-cleaving
protease activity, I wish to emphasize that this abnormal-trophils from children in the acute phase of STX-associ-
ated HUS adhere to endothelial cells more tightly than ity is frequent in other diseases such as liver cirrhosis or
end-stage renal failure, and even in physiologic condi-do normal neutrophils and induce endothelial injury by
degrading endothelial cell fibronectin, possibly by the tions such as old age and pregnancy. Thus, decreased
vWF protease activity is a nonspecific finding that mightrelease of neutrophil-specific proteases [78]. In vitro,
STX promotes massive leukocyte adhesion and trans- have a poor diagnostic value but that, however, might
help identify patients who might benefit from plasmamigration to endothelium under flow conditions by up-
regulating endothelial expression of adhesive proteins infusion or exchange.
Dr. Ruggenenti: I suggest a note of caution beforeand chemokines (abstract; Zoja et al, J Am Soc Nephrol
10:595A, 1999). Conceivably, the same sequence of events one decides to infuse or exchange plasma on the basis
of decreased vWF-cleaving protease activity. Indeed, re-could be precipitated by CsA-induced up-regulation of
adhesive molecules. This might enhance the prothrom- gardless of the activity of the protease, plasma therapy
is invariably recommended in adult forms and in chil-botic effects discussed before that are sustained by CsA-
induced vasoconstriction and increased shear stress. dren with non-STX-associated HUS. On the other hand,
Dr. Gina Gregorini (Division of Nephrology, Spedali whether decreased vWF-cleaving protease activity is a
Civili, Brescia, Italy): I have a practical question. We often cause or just a sign of recurrent HUS or TTP is not
see sporadic cases that are difficult to classify. In particu- definitely established. Finding that plasma therapy re-
lar, the diagnosis of STX-associated HUS cannot be stores protease activity and that this restoration occurs
definitely confirmed or excluded because the history is in parallel with disease remission does not necessarily
not clear and the toxin was not looked for or was looked imply that normalization of protease activity is the deter-
for only after resolution of the acute episode or after minant of response to plasma. Indeed, evidence that
the patient already had received antibiotics. What do plasma is effective even in forms with normal protease
you suggest for these patients who develop end-stage activity implies that other mechanisms might be involved
renal disease? Should a renal transplant be discouraged? and that these mechanisms might play a major role even
Dr. Ruggenenti: Finding a high titer of circulating in recurrent forms.
anti-STX antibodies might suggest a diagnosis of STX As for the nonspecificity of decreased vWF-cleaving
HUS even if the history is uncertain. On the other hand, protease activity, I wish to point out that this abnormality
if there is another case in the family or the patient denies has been reported during the acute phase of STX-associ-
a history of diarrhea, the possibility of a non-STX-associ- ated HUS (Loirat C, unpublished data). Indeed, persis-
ated form is extremely high and the transplant is at in- tence of the abnormality after disease remission is the
creased risk. In all these cases, as well as in cases in which finding that distinguishes familial/recurrent forms with
a diagnosis of STX HUS is not definitely established, a genetically determined defect from sporadic forms with
patients should be studied to look for recognized factor acquired and transient protease abnormalities.
H or vWF-cleaving protease abnormalities. These studies
Reprint requests to Dr. P. Ruggenenti, Negri Bergamo Laboratories,are expensive and time consuming, but they are largely
Via Gavazzeni 11, 24125 Bergamo, Italy.
cost-effective considering the tremendous medical, psy- E-mail: Ruggenenti@marionegri.it
chologic, and economic drawbacks of an unsuccessful
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